Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma

J. Vela-Ojeda, M. A. García-Ruiz Esparza, E. Reyes-Maldonado, L. Jiménez-Zamudio, E. García-Latorre, M. Moreno-Lafont, I. Estrada-García, H. Mayani, L. Montiel-Cervantes, F. Tripp-Villanueva, M. Ayala-Sánchez, L. D. García-León, J. R. Borbolla-Escoboza

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Between June 2003 and November 2004, we collected mobilized peripheral blood units from 29 patients with non-Hodgkin's lymphoma and multiple myeloma for autologous peripheral blood stem cell transplantation. They received granulocyte colony-stimulating factor (G-CSF) (16 μg/kg/day) for a total of 5 days. Immediately before and 3 h after the fourth and fifth dose of G-CSF, we performed flow cytometry analysis to quantify: T cells (CD3+CD4+, CD3+CD8+), B cells (CD19+), NK cells (CD3-CD16+CD56+), NKT cells (CD3+CD16+CD56+), type 1 dendritic cells (DC1) (lin-HLA-DR+CD11c+), type 2 dendritic cells (DC2) (lin-HLA-DR+CD123+), regulatory T cells (Tregs) (CD4+CD25+), and activated T cells (CD3+HLA-DR+). All cell subsets were mobilized after G-CSF treatment with the exception of B, NK, and NKT lymphocytes. The median number of Treg cells before and after G-CSF was statistically different (29±14.9×106/l vs 70.1±46.1×106/l, P<0.02). DCs were mobilized significantly with a 5.9-fold increase in DC2 (15.1±30.3×106/l vs 89.8±81.0×106/l, P<0.02) and a 2.6-fold increase for DC1 (41±42.5×106/l vs 109.5±58.0×106/l, P<0.04). Patients received a mean of 3.1±1.2×107/kg NK cells, 1.3±0.9×107/kg NKT cells, 0.41±0.29×107/kg DC1, 0.2±0.22×107/kg DC2, and 1.8±1.9×107/kg Tregs. In conclusion, intermediate doses of G-CSF induce mobilization of different lymphocyte subsets, with the exception of B, NK, and NKT cells. The mobilization of certain suppressive populations (DC2 and Treg) could be in theory deleterious, at least in patients with cancer. © Springer-Verlag 2006.
Original languageAmerican English
Pages (from-to)308-314
Number of pages276
JournalAnnals of Hematology
DOIs
StatePublished - 1 May 2006

Fingerprint

lymphocytes
Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Non-Hodgkin's Lymphoma
Dendritic Cells
set theory
blood
Natural Killer T-Cells
Lymphocytes
HLA-DR Antigens
dosage
Natural Killer Cells
cells
Regulatory T-Lymphocytes
B-Lymphocytes
T-Lymphocytes
Peripheral Blood Stem Cell Transplantation
Lymphocyte Subsets
Lymphoma
Flow Cytometry

Cite this

@article{6080f4991d524bd8b3eb4c7e8dfe426d,
title = "Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma",
abstract = "Between June 2003 and November 2004, we collected mobilized peripheral blood units from 29 patients with non-Hodgkin's lymphoma and multiple myeloma for autologous peripheral blood stem cell transplantation. They received granulocyte colony-stimulating factor (G-CSF) (16 μg/kg/day) for a total of 5 days. Immediately before and 3 h after the fourth and fifth dose of G-CSF, we performed flow cytometry analysis to quantify: T cells (CD3+CD4+, CD3+CD8+), B cells (CD19+), NK cells (CD3-CD16+CD56+), NKT cells (CD3+CD16+CD56+), type 1 dendritic cells (DC1) (lin-HLA-DR+CD11c+), type 2 dendritic cells (DC2) (lin-HLA-DR+CD123+), regulatory T cells (Tregs) (CD4+CD25+), and activated T cells (CD3+HLA-DR+). All cell subsets were mobilized after G-CSF treatment with the exception of B, NK, and NKT lymphocytes. The median number of Treg cells before and after G-CSF was statistically different (29±14.9×106/l vs 70.1±46.1×106/l, P<0.02). DCs were mobilized significantly with a 5.9-fold increase in DC2 (15.1±30.3×106/l vs 89.8±81.0×106/l, P<0.02) and a 2.6-fold increase for DC1 (41±42.5×106/l vs 109.5±58.0×106/l, P<0.04). Patients received a mean of 3.1±1.2×107/kg NK cells, 1.3±0.9×107/kg NKT cells, 0.41±0.29×107/kg DC1, 0.2±0.22×107/kg DC2, and 1.8±1.9×107/kg Tregs. In conclusion, intermediate doses of G-CSF induce mobilization of different lymphocyte subsets, with the exception of B, NK, and NKT cells. The mobilization of certain suppressive populations (DC2 and Treg) could be in theory deleterious, at least in patients with cancer. {\circledC} Springer-Verlag 2006.",
author = "J. Vela-Ojeda and {Garc{\'i}a-Ruiz Esparza}, {M. A.} and E. Reyes-Maldonado and L. Jim{\'e}nez-Zamudio and E. Garc{\'i}a-Latorre and M. Moreno-Lafont and I. Estrada-Garc{\'i}a and H. Mayani and L. Montiel-Cervantes and F. Tripp-Villanueva and M. Ayala-S{\'a}nchez and Garc{\'i}a-Le{\'o}n, {L. D.} and Borbolla-Escoboza, {J. R.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1007/s00277-006-0090-8",
language = "American English",
pages = "308--314",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma. / Vela-Ojeda, J.; García-Ruiz Esparza, M. A.; Reyes-Maldonado, E.; Jiménez-Zamudio, L.; García-Latorre, E.; Moreno-Lafont, M.; Estrada-García, I.; Mayani, H.; Montiel-Cervantes, L.; Tripp-Villanueva, F.; Ayala-Sánchez, M.; García-León, L. D.; Borbolla-Escoboza, J. R.

In: Annals of Hematology, 01.05.2006, p. 308-314.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma

AU - Vela-Ojeda, J.

AU - García-Ruiz Esparza, M. A.

AU - Reyes-Maldonado, E.

AU - Jiménez-Zamudio, L.

AU - García-Latorre, E.

AU - Moreno-Lafont, M.

AU - Estrada-García, I.

AU - Mayani, H.

AU - Montiel-Cervantes, L.

AU - Tripp-Villanueva, F.

AU - Ayala-Sánchez, M.

AU - García-León, L. D.

AU - Borbolla-Escoboza, J. R.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Between June 2003 and November 2004, we collected mobilized peripheral blood units from 29 patients with non-Hodgkin's lymphoma and multiple myeloma for autologous peripheral blood stem cell transplantation. They received granulocyte colony-stimulating factor (G-CSF) (16 μg/kg/day) for a total of 5 days. Immediately before and 3 h after the fourth and fifth dose of G-CSF, we performed flow cytometry analysis to quantify: T cells (CD3+CD4+, CD3+CD8+), B cells (CD19+), NK cells (CD3-CD16+CD56+), NKT cells (CD3+CD16+CD56+), type 1 dendritic cells (DC1) (lin-HLA-DR+CD11c+), type 2 dendritic cells (DC2) (lin-HLA-DR+CD123+), regulatory T cells (Tregs) (CD4+CD25+), and activated T cells (CD3+HLA-DR+). All cell subsets were mobilized after G-CSF treatment with the exception of B, NK, and NKT lymphocytes. The median number of Treg cells before and after G-CSF was statistically different (29±14.9×106/l vs 70.1±46.1×106/l, P<0.02). DCs were mobilized significantly with a 5.9-fold increase in DC2 (15.1±30.3×106/l vs 89.8±81.0×106/l, P<0.02) and a 2.6-fold increase for DC1 (41±42.5×106/l vs 109.5±58.0×106/l, P<0.04). Patients received a mean of 3.1±1.2×107/kg NK cells, 1.3±0.9×107/kg NKT cells, 0.41±0.29×107/kg DC1, 0.2±0.22×107/kg DC2, and 1.8±1.9×107/kg Tregs. In conclusion, intermediate doses of G-CSF induce mobilization of different lymphocyte subsets, with the exception of B, NK, and NKT cells. The mobilization of certain suppressive populations (DC2 and Treg) could be in theory deleterious, at least in patients with cancer. © Springer-Verlag 2006.

AB - Between June 2003 and November 2004, we collected mobilized peripheral blood units from 29 patients with non-Hodgkin's lymphoma and multiple myeloma for autologous peripheral blood stem cell transplantation. They received granulocyte colony-stimulating factor (G-CSF) (16 μg/kg/day) for a total of 5 days. Immediately before and 3 h after the fourth and fifth dose of G-CSF, we performed flow cytometry analysis to quantify: T cells (CD3+CD4+, CD3+CD8+), B cells (CD19+), NK cells (CD3-CD16+CD56+), NKT cells (CD3+CD16+CD56+), type 1 dendritic cells (DC1) (lin-HLA-DR+CD11c+), type 2 dendritic cells (DC2) (lin-HLA-DR+CD123+), regulatory T cells (Tregs) (CD4+CD25+), and activated T cells (CD3+HLA-DR+). All cell subsets were mobilized after G-CSF treatment with the exception of B, NK, and NKT lymphocytes. The median number of Treg cells before and after G-CSF was statistically different (29±14.9×106/l vs 70.1±46.1×106/l, P<0.02). DCs were mobilized significantly with a 5.9-fold increase in DC2 (15.1±30.3×106/l vs 89.8±81.0×106/l, P<0.02) and a 2.6-fold increase for DC1 (41±42.5×106/l vs 109.5±58.0×106/l, P<0.04). Patients received a mean of 3.1±1.2×107/kg NK cells, 1.3±0.9×107/kg NKT cells, 0.41±0.29×107/kg DC1, 0.2±0.22×107/kg DC2, and 1.8±1.9×107/kg Tregs. In conclusion, intermediate doses of G-CSF induce mobilization of different lymphocyte subsets, with the exception of B, NK, and NKT cells. The mobilization of certain suppressive populations (DC2 and Treg) could be in theory deleterious, at least in patients with cancer. © Springer-Verlag 2006.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33646713892&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=33646713892&origin=inward

U2 - 10.1007/s00277-006-0090-8

DO - 10.1007/s00277-006-0090-8

M3 - Article

C2 - 16525786

SP - 308

EP - 314

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -